We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Syneos Health Inc | NASDAQ:SYNH | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 42.98 | 42.96 | 42.99 | 0 | 01:00:00 |
The study, which was released during a Super Session at the BIO International Convention in Boston, Massachusetts, provides a review of biopharmaceutical dealmakers’ intentions around licensing and acquisitions for the next twelve months and identifies areas of greatest opportunity for buyers and sellers. The 10th edition of the study also follows persistent trends that have shaped the past decade of dealmaking. Download the full 2018 Dealmakers' Intentions Study.
“Large-cap consolidations may still be in the offering, but the distinguishing trend of the last decade is the growth in emerging companies and the new financing options available to them,” said Neel Patel, Managing Director, Commercial Strategy & Planning at Syneos Health Consulting (previously INC Research/inVentiv Health Consulting). “We predict 2018 will follow suit, with emerging companies having many cards to play as long as they focus on clearly demonstrating value-based product differentiation while avoiding common dealmaking pitfalls.”
Key findings include:
M&A Landscape Continues Bullish Run…
….While Buyers Seem to Become a Bit More Risk Averse
Robust Investor Appetite Fuels New Company Formation
Supply and Demand Imbalance Indicate Areas for Assessment
Learn more:
About Syneos Health ConsultingSyneos Health Consulting is an industry-leading consulting firm specializing in the biopharmaceutical industry and part of Syneos Health, the only fully integrated biopharmaceutical solutions organization. We provide services across a comprehensive range of key areas, including commercial strategy and planning, medical affairs, risk and program management and pricing and market access. Recognized by Forbes magazine as one of America’s Best Management Consulting Firms for three years running, our industry focus and depth of functional expertise, combined with strong scientific and market knowledge, uniquely position us to tackle highly complex business and market challenges to develop actionable strategies for our clients. For more information, please visit syneoshealth.com/solutions/consulting.
Contact: Investor Relations Contact: Press/Media Contact: Ronnie Speight Danielle DeForgeVice President, Investor Relations Senior Director, External Communications +1 919 745 2745 +1 202 210 5992Investor.Relations@syneoshealth.com danielle.deforge@syneoshealth.com
1 Year Syneos Health Chart |
1 Month Syneos Health Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions